Underdilation strategy for TIPS placement reduces incidence of overt hepatic encephalopathy without affecting clinical efficacy and survival: results of a multicenter prospective Italian study

D. Saltini,S. Nardelli,V. Addotti,L. Biribin,T. Guasconi,S. Gioia,C. Caporali,M. Bianchini,M. Rosi,D. Roccarina,L. Ridola,F. Casari,F. Prampolini,F. Indulti,B. Cuffari,L. Ragozzino,N. De Maria,A. Colecchia,M. Senzolo,M. Merli,F. Marra,O. Riggio,F. Vizzutti,F. Schepis
DOI: https://doi.org/10.1016/j.dld.2024.01.015
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Introduction Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established treatment for portal hypertension complications in patients with cirrhosis. Overt hepatic encephalopathy (OHE) is the most feared complication of TIPS, significantly impacting the patient's quality of life and care giver burden. TIPS underdilation to <8 mm is a promising approach to reduce the incidence of this complication. Aims To compare the probability of OHE between patients with underdilated TIPS and those with TIPS dilated to ≥8 mm. The secondary objective was to evaluate the recurrence of ascites/bleeding and the 2-year mortality rate. Materials and Methods This was a prospective multicenter observational study conducted at four referral Centers participating in the Italian-TIPS-Registry. Consecutive patients who received TIPS from April 2012 to March 2022 were included. Competitive risk analysis was conducted for primary and secondary outcomes. Results Out of 574 enrolled patients, 284 (49%) received TIPS underdilated to <8mm. The 1-year incidence of OHE was significantly higher in ≥8mm group compared to the underdilated group (55% vs. 35%; p<0.001), regardless of TIPS indication. Multivariable analysis identified older age, elevated INR, low sodium, and history of previous OHE as independent predictors of OHE; conversely, underdilated TIPS exerted a significant protective role (sHR 0.51; p<0.001). No significant difference in TIPS dysfunction rate was observed. Clinical efficacy was unaffected by the underdilation approach, as demonstrated by the lack of significant differences in recurrence of ascites requiring large-volume paracentesis or rebleeding between groups. Regardless of TIPS indication, the 2-year mortality rates did not significantly differ between the underdilated and ≥8 mm groups (26% vs. 30%; p=0.4). Conclusion The study confirms that the TIPS underdilation strategy significantly reduces the burden of OHE while maintaining clinical efficacy, and does not negatively impact mortality when compared to the standard dilation strategy.
gastroenterology & hepatology
What problem does this paper attempt to address?